Advocacy intelligence hub — real-time data for patient organizations
DROXIA: FDA approved
To reduce the frequency of painful crises and to reduce the need for blood transfusions in adult patients with sickle cell anemia with recurrent moderate to severe painful crises (generally at least 3 during the preceding 12 months).
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
DROXIA
(HYDROXYUREA)Orphan drugWaylis Therapeutics LLC
Browse all OBSOLETE: Sickle cell disease associated with another hemoglobin anomaly news →
View all OBSOLETE: Sickle cell disease associated with another hemoglobin anomaly specialists →